<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>

<title>Epocrates Drug Updates</title>
<description>Have the latest drug information at your fingertips with Epocrates mobile and online drug databases. Epocrates drug information is trusted by more than 1,400,000 healthcare professionals to be objective, accurate, current, concise, and clinically relevant. Learn more at www.epocrates.com</description>
<link>http://www.epocrates.com/company/content/updates/index.html</link>
<language>en-us</language>
<webMaster>clinical@epocrates.com</webMaster>
<image>
	<url>http://www.epocrates.com/img/company/content/logo_feed.gif</url>
    <title>Epocrates.com</title>
	<link>http://www.epocrates.com/company/content/updates/index.html</link>
	<description>Epocrates.com</description>
	<width>144</width>
	<height>29</height>
</image>

<item>
<pubDate>Wed, 25 Jan 2012 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Tysabri</title>
<description><![CDATA[ The FDA released an update about the risk of progressive multifocal leukoencephalopathy (PML) associated with the immunomodulator drug, Tysabri (natalizumab), used to treat multiple sclerosis or Crohn disease.  A third PML risk factor has been identified, anti-JCV antibodies, in addition to longer Tysabri treatment duration and prior immunosuppressant therapy.  Healthcare professionals should carefully evaluate the risks and benefits of Tysabri treatment in patients found to be anti-JCV antibody positive and have one or more of the other known risk factors for PML. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1034015/Tysabri/Contraindications+Cautions</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1034015/Tysabri/Contraindications+Cautions</guid>
</item>

<item>
<pubDate>Wed, 25 Jan 2012 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for Maxalt</title>
<description><![CDATA[ The FDA recently approved the selective serotonin agonist, Maxalt and Maxalt-MLT (rizatriptan) to treat migraine headaches in pediatric patients, 6-17 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/102938/Maxalt/Pediatric+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/102938/Maxalt/Pediatric+Dosing</guid>
</item>

<item>
<pubDate>Wed, 18 Jan 2012 08:00:00 GMT</pubDate>
<title>New Generic Monograph for Cromolyn</title>
<description><![CDATA[ The generic formulation of the oral mast cell stabilizer, cromolyn (first-time generic for Gastrocrom), recently became available to treat symptoms of mastocytosis in adult and pediatric patients greater than two years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a828/cromolyn</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a828/cromolyn</guid>
</item>

<item>
<pubDate>Wed, 11 Jan 2012 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Onfi</title>
<description><![CDATA[ The FDA recently approved the long-acting benzodiazepine, Onfi (clobazam), for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in adult and pediatric patients greater than two years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6257/Onfi</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6257/Onfi</guid>
</item>

<item>
<pubDate>Wed, 4 Jan 2012 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Multaq</title>
<description><![CDATA[ The FDA has completed a safety review for the oral antiarrhythmic, Multaq (dronedarone), concluding that the drug should not be prescribed to patients with permanent atrial fibrillation (AF), due to increased risk of serious cardiovascular events, including death.  All non-permanent (paroxysmal or persistent) AF patients receiving Multaq should have electrocardiogram monitoring every 3 months; discontinue Multaq or be cardioverted if found to be in AF; and receive appropriate antithrombotic therapy while taking Multaq. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5435/Multaq</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5435/Multaq</guid>
</item>

<item>
<pubDate>Wed, 4 Jan 2012 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Infant Acetaminophen Products</title>
<description><![CDATA[ The FDA recently communicated a warning for acetaminophen products marketed for infants.  A new concentration is available (160 mg/5 mL) which affects the volume of liquid given to an infant.  Other infant acetaminophen products are available in 80 mg/0.8 mL and 80 mg/mL concentrations.  To avoid confusion and potential dosing errors, instruct caregivers to carefully read and verify the concentration, dosage, and directions for use on the product label and only use the dosing device provided with the product. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1ba5856/Little+Fevers+Fever-Pain+Reliever</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1ba5856/Little+Fevers+Fever-Pain+Reliever</guid>
</item>

<item>
<pubDate>Wed, 14 Dec 2011 08:00:00 GMT</pubDate>
<title>New Generic Monograph for Caduet</title>
<description><![CDATA[ The FDA recently approved the generic formulation for amlodipine/atorvastatin (Caduet) to treat patients who need therapy with both a calcium channel blocker and a statin. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a3703/amlodipine-atorvastatin</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a3703/amlodipine-atorvastatin</guid>
</item>

<item>
<pubDate>Wed, 7 Dec 2011 08:00:00 GMT</pubDate>
<title>New Generic Monograph for Atorvastatin</title>
<description><![CDATA[ The FDA recently approved the generic formulation for atorvastatin (Lipitor) to treat various dyslipidemias in adult and pediatric patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a879/atorvastatin</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a879/atorvastatin</guid>
</item>

<item>
<pubDate>Wed, 30 Nov 2011 08:00:00 GMT</pubDate>
<title>Breast Cancer Indication Revoked for Avastin</title>
<description><![CDATA[ The FDA recently revoked the approval of Avastin (bevacizumab) for the treatment of breast cancer due to lack of safety and efficacy data for that indication.  The drug is still approved for the treatment of metastatic colorectal cancer, progressive glioblastoma multiforme, non-small cell lung cancer, and metastatic renal cell cancer. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1013620/Avastin/Adult+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1013620/Avastin/Adult+Dosing</guid>
</item>

<item>
<pubDate>Wed, 30 Nov 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Duexis</title>
<description><![CDATA[ The FDA recently approved the combination NSAID/H2 blocker, Duexis (ibuprofen/famotidine), to treat osteoarthritis and rheumatoid arthritis in patients at risk for upper gastrointestinal ulcers resulting from chronic NSAID use. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6227/Duexis</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6227/Duexis</guid>
</item>

<item>
<pubDate>Wed, 16 Nov 2011 08:00:00 GMT</pubDate>
<title>New Generic Monograph for Tranexamic Acid</title>
<description><![CDATA[ The FDA recently approved the generic intravenous formulation of tranexamic acid (brand name Cyklokapron), used to reduce or prevent bleeding in hemophilia patients following dental procedures. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a3880/tranexamic+acid</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a3880/tranexamic+acid</guid>
</item>

<item>
<pubDate>Wed, 9 Nov 2011 08:00:00 GMT</pubDate>
<title>New Indication for Xarelto</title>
<description><![CDATA[ The FDA recently approved the factor Xa inhibitor, Xarelto (rivaroxaban), to prevent stroke and thromboembolism in patients with nonvalvular atrial fibrillation.  The drug was originally approved for the prophylaxis of deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6103/Xarelto</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6103/Xarelto</guid>
</item>

<item>
<pubDate>Wed, 2 Nov 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Nexplanon</title>
<description><![CDATA[ The FDA recently approved the implantable progestin-only contraceptive, Nexplanon (etonogestrel subdermal implant), for use in adult female patients.  Nexplanon comes in a preloaded applicator and contains barium to make the implant visible on X-ray or CT scan. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6221/Nexplanon</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6221/Nexplanon</guid>
</item>

<item>
<pubDate>Wed, 26 Oct 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Xigris</title>
<description><![CDATA[ Based on recent clinical trial data, Xigris (drotrecogin alfa), was voluntarily withdrawn from the market when it failed to show a survival benefit for patients with severe sepsis and septic shock.  New patients should not start Xigris, and treatment should be stopped in patients currently receiving the drug. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2550/Xigris</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2550/Xigris</guid>
</item>

<item>
<pubDate>Wed, 19 Oct 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Sprycel</title>
<description><![CDATA[ The FDA recently notified healthcare professionals about the risk of pulmonary arterial hypertension (PAH) associated with the tyrosine kinase inhibitor, Sprycel (dasatinib).  Patients should be evaluated before, during, and after treatment with Sprycel for signs and symptoms of PAH, including shortness of breath, fatigue, and peripheral edema. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4413/Sprycel</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4413/Sprycel</guid>
</item>

<item>
<pubDate>Wed, 12 Oct 2011 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for Remicade</title>
<description><![CDATA[ The FDA recently approved the tumor necrosis factor (TNF) inhibitor Remicade (infliximab) to treat active moderate to severe ulcerative colitis in children older than 6 years who have failed conventional therapies. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022174/Remicade/Pediatric+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022174/Remicade/Pediatric+Dosing</guid>
</item>

<item>
<pubDate>Wed, 28 Sep 2011 08:00:00 GMT</pubDate>
<title>New Indication for Prolia</title>
<description><![CDATA[ The FDA recently approved a new indication for the RANKL inhibitor, Prolia (denosumab), to increase bone mass in high fracture risk patients receiving adjuvant aromatase inhibitor therapy for breast cancer or androgen deprivation therapy for nonmetastatic prostate cancer. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015749/Prolia/Adult+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015749/Prolia/Adult+Dosing</guid>
</item>

<item>
<pubDate>Wed, 28 Sep 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Xalkori</title>
<description><![CDATA[ The FDA recently approved Xalkori (crizotinib), a kinase inhibitor used to treat locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase (ALK) positive. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6190/Xalkori</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6190/Xalkori</guid>
</item>

<item>
<pubDate>Wed, 21 Sep 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Ondansetron</title>
<description><![CDATA[ Based on an ongoing safety review, the FDA issued an alert for ondansetron (available as generic and brands Zofran, Zofran ODT, and Zuplenz).  The 5-HT3 receptor antagonist drug used to treat nausea and vomiting may increase the risk of QT interval prolongation, potentially leading to abnormal heart rhythms, including Torsade de Pointes.  Ondansetron should be avoided in patients with congenital long QT syndrome.  Patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or concurrent QT prolonging drugs should receive ECG monitoring while receiving ondansetron. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1031441/ondansetron/Contraindications+Cautions</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1031441/ondansetron/Contraindications+Cautions</guid>
</item>

<item>
<pubDate>Wed, 14 Sep 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Tumor Necrosis Factor-alpha Blockers</title>
<description><![CDATA[ The Boxed Warning for the entire class of Tumor Necrosis Factor-alpha blockers (Cimzia, Enbrel, Humira, Remicade, and Simponi) has been updated to include the risk of infection from Legionella and Listeria.  The labeling for these agents already contains warnings about the risk for serious infections caused by other bacteria, mycobacteria, fungi, viruses, parasites, and other opportunistic pathogens.  The risks and benefits should be considered prior to initiating therapy in patients with chronic or recurrent infections and patients with underlying conditions that may predispose them to infection. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b2069/Enbrel/Black+Box+Warnings</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b2069/Enbrel/Black+Box+Warnings</guid>
</item>

<item>
<pubDate>Wed, 7 Sep 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Reclast</title>
<description><![CDATA[ The FDA recently notified healthcare professionals about the risk of kidney failure associated with Reclast (zoledronic acid).  Reclast is contraindicated in patients with a creatinine clearance less than 35 mL/min or evidence of acute renal impairment.  Patients should be screened prior to therapy for risk factors, including renal impairment and/or concurrent use of nephrotoxic drugs or diuretics, and should be monitored while receiving Reclast. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4688/Reclast</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4688/Reclast</guid>
</item>

<item>
<pubDate>Wed, 31 Aug 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Celexa</title>
<description><![CDATA[ The FDA recently communicated labeling changes for the selective serotonin reuptake inhibitor, Celexa (citalopram), because it can cause dose-dependent QT interval prolongation.  Citalopram should not be prescribed at doses greater than 40 mg per day, due to an increased risk of abnormal heart rhythms and lack of additional therapeutic benefit.  Citalopram should not be used in patients with congenital long QT syndrome or uncorrected electrolyte abnormalities, and should be used with caution in patients with other risk factors for Torsade de Pointes. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a497/Celexa</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a497/Celexa</guid>
</item>

<item>
<pubDate>Wed, 31 Aug 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Anascorp</title>
<description><![CDATA[ The FDA recently approved Anascorp (Centruroides immune Fab), the first specific treatment for Centruroides scorpion stings.  This genus of venomous scorpions is common to the southwest United States, primarily Arizona.  Untreated stings can be life-threatening, especially in infants and children. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6163/Anascorp</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6163/Anascorp</guid>
</item>

<item>
<pubDate>Wed, 24 Aug 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Complera</title>
<description><![CDATA[ The FDA recently approved the once-daily three-drug combination, Complera (emtricitabine/rilpivirine/tenofovir), to treat HIV infection in treatment-naïve adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6157/Complera</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6157/Complera</guid>
</item>

<item>
<pubDate>Wed, 17 Aug 2011 08:00:00 GMT</pubDate>
<title>New Generic Drug Monograph for Fondaparinux</title>
<description><![CDATA[ The FDA recently approved the anticoagulant, fondaparinux (first-time generic for Arixtra), for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2661/fondaparinux</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2661/fondaparinux</guid>
</item>

<item>
<pubDate>Wed, 10 Aug 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Brilinta</title>
<description><![CDATA[ The FDA recently approved the oral platelet inhibitor, Brilinta (ticagrelor), in combination with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6147/Brilinta</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6147/Brilinta</guid>
</item>

<item>
<pubDate>Wed, 3 Aug 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Natroba</title>
<description><![CDATA[ The FDA recently approved the topical pediculicide, Natroba (spinosad topical), for the treatment of head lice in patients greater than four years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6142/Natroba</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6142/Natroba</guid>
</item>

<item>
<pubDate>Wed, 27 Jul 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Chantix</title>
<description><![CDATA[ The FDA recently strengthened warnings about the risk of cardiovascular adverse effects, including angina pectoris, nonfatal myocardial infarction, and peripheral vascular disease, associated with Chantix (varenicline) for smoking cessation.  Healthcare professionals should weigh the potential benefits of Chantix against its potential risks; keeping in mind that smoking is an independent and major risk factor for cardiovascular disease, and smoking cessation is of particular importance in this patient population.  The drug label has also been updated to allow patients to choose a quit date either 7 days after starting Chantix, or between days 8 and 35 of treatment. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4391/Chantix</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4391/Chantix</guid>
</item>

<item>
<pubDate>Wed, 27 Jul 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Multaq</title>
<description><![CDATA[ Recent clinical trial data found two-fold increases in death, stroke, and hospitalizations for heart failure associated with the use of Multaq (dronedarone) in patients with permanent atrial fibrillation.  It is not clear at this time whether the trial results apply to patients with paroxysmal or persistent atrial fibrillation or atrial flutter.  Based on the trial data, the FDA is currently recommending that healthcare professionals not prescribe Multaq for patients with permanent atrial fibrillation. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5435/Multaq</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5435/Multaq</guid>
</item>

<item>
<pubDate>Wed, 20 Jul 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Xarelto</title>
<description><![CDATA[ The FDA recently approved the oral factor Xa inhibitor, Xarelto (rivaroxaban), for the prophylaxis of deep vein thrombosis in adult patients undergoing knee or hip replacement surgery. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6103/Xarelto</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6103/Xarelto</guid>
</item>

<item>
<pubDate>Wed, 13 Jul 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Tamiflu</title>
<description><![CDATA[ The FDA notified healthcare professionals about changes being made to Tamiflu (oseltamivir) oral suspension.  A new 6 mg/mL concentration will be available to replace the 12 mg/mL formulation.  The lower concentration is less likely to froth when shaken, therefore allowing for more accurate dose measurement.  The 12 mg/mL concentration will remain in some pharmacies until current supplies expire, so patients could potentially receive either concentration from their pharmacy during the 2011-2012 influenza season.  The FDA recommends that prescriptions for Tamiflu suspension include the new concentration (6 mg/mL) and the dose in milliliters to avoid the potential for medication error. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2172/Tamiflu</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2172/Tamiflu</guid>
</item>

<item>
<pubDate>Wed, 6 Jul 2011 08:00:00 GMT</pubDate>
<title>New First-Time Generic Monograph for Azelastine Nasal</title>
<description><![CDATA[ The FDA recently approved a first-time generic for azelastine nasal (generic for Astelin) to treat nasal symptoms of allergic rhinitis in adult and pediatric patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1863/azelastine+nasal</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1863/azelastine+nasal</guid>
</item>

<item>
<pubDate>Wed, 29 Jun 2011 08:00:00 GMT</pubDate>
<title>New First-Time Generic Monograph for Triamcinolone Nasal</title>
<description><![CDATA[ The FDA recently approved a first-time generic for triamcinolone nasal (generic for Nasacort AQ) to treat nasal symptoms of allergic rhinitis in adult and pediatric patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2035/triamcinolone+nasal</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2035/triamcinolone+nasal</guid>
</item>

<item>
<pubDate>Wed, 29 Jun 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Erythropoiesis-Stimulating Agents</title>
<description><![CDATA[ The FDA recently modified recommendations for the erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) in patients with chronic kidney disease.  In order to reduce the risk of serious adverse cardiovascular events associated with targeting a hemoglobin level greater than 11 g/dL, therapy should be individualized to the lowest possible ESA dose to reduce the need for transfusions. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2027/Epogen</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2027/Epogen</guid>
</item>

<item>
<pubDate>Wed, 22 Jun 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Pioglitazone</title>
<description><![CDATA[ The FDA issued an update on the potential for developing bladder cancer associated with the diabetes drug pioglitazone, when used alone (Actos) or in combination as pioglitazone/glimepiride (Duetact) or pioglitazone/metformin (ACTOSplus met, ACTOSplus met XR).  This increased risk of bladder cancer was noted among patients with the longest exposure and highest cumulative dose of pioglitazone.  Pioglitazone products should not be used in patients with active bladder cancer and should be used with caution in patients with a history of bladder cancer. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1032051/Actos/Contraindications+Cautions</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1032051/Actos/Contraindications+Cautions</guid>
</item>

<item>
<pubDate>Wed, 15 Jun 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Simvastatin</title>
<description><![CDATA[ The FDA recently recommended a dose limitation for simvastatin, when used alone (Zocor, generic) or in combination as ezetimibe/simvastatin (Vytorin) or niacin/simvastatin (Simcor).  Patients taking simvastatin 80 mg daily are at an increased risk of myopathy and rhabdomyolysis, particularly in the first 12 months of treatment. Several other medications, when taken concomitantly with simvastatin, can increase simvastatin levels and may necessitate either a simvastatin dose reduction or switch to another statin with less drug-drug interaction potential. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1439/simvastatin</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1439/simvastatin</guid>
</item>

<item>
<pubDate>Wed, 8 Jun 2011 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for Faslodex</title>
<description><![CDATA[ The FDA recently approved the anti-estrogenic drug, Faslodex (fulvestrant), for use in female pediatric patients with progressive precocious puberty associated with McCune-Albright Syndrome. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022712/Faslodex/Pediatric+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022712/Faslodex/Pediatric+Dosing</guid>
</item>

<item>
<pubDate>Wed, 1 Jun 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Daliresp</title>
<description><![CDATA[ The FDA recently approved the oral phosphodiesterase type 4 (PDE4) inhibitor, Daliresp (roflumilast), to reduce the risk of exacerbations in adult patients with chronic obstructive pulmonary disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6076/Daliresp</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6076/Daliresp</guid>
</item>

<item>
<pubDate>Wed, 25 May 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Tradjenta</title>
<description><![CDATA[ The FDA recently approved the dipeptidyl peptidase-4 (DPP-4) inhibitor Tradjenta (linagliptin) to improve glycemic control in adult patients with type 2 diabetes. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6069/Tradjenta</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6069/Tradjenta</guid>
</item>

<item>
<pubDate>Wed, 25 May 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Horizant</title>
<description><![CDATA[ The FDA recently approved Horizant (gabapentin enacarbil), the extended-release prodrug for gabapentin, to treat moderate to severe restless legs syndrome in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6067/Horizant</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6067/Horizant</guid>
</item>

<item>
<pubDate>Wed, 18 May 2011 08:00:00 GMT</pubDate>
<title>New Pediatric Indication Approved for Nexium</title>
<description><![CDATA[ The FDA recently approved the use of the intravenous formulation of the proton pump inhibitor Nexium (esomeprazole) for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis in patients greater than 1 month of age when oral therapy is not possible or appropriate. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022340/Nexium/Pediatric+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022340/Nexium/Pediatric+Dosing</guid>
</item>

<item>
<pubDate>Wed, 11 May 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Staxyn</title>
<description><![CDATA[ Vardenafil, a phosphodiesterase-5 inhibitor used to treat erectile dysfunction, is now available as an orally disintegrating tablet (ODT) under the brand name Staxyn. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a6054/Staxyn/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a6054/Staxyn/</guid>
</item>

<item>
<pubDate>Wed, 4 May 2011 08:00:00 GMT</pubDate>
<title>New Indications Approved for Rituxan</title>
<description><![CDATA[ The FDA recently approved the use of Rituxan (rituximab), a monoclonal antibody that depletes B cells, in combination with glucocorticoids to treat vasculitis caused by Wegeners granulomatosis (WG) and microscopic polyangiitis (MPA). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1623/Rituxan/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1623/Rituxan/</guid>
</item>

<item>
<pubDate>Wed, 27 Apr 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert Update for Tysabri</title>
<description><![CDATA[ The FDA added safety information about other immunomodulator drugs taken by patients and how they may affect the risk of progressive multifocal leukoencephalopathy (PML) associated with the use of Tysabri (natalizumab) to treat multiple sclerosis and Crohns disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4015/Tysabri/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4015/Tysabri/</guid>
</item>

<item>
<pubDate>Wed, 27 Apr 2011 08:00:00 GMT</pubDate>
<title>Expanded Pediatric Dosing for Menactra</title>
<description><![CDATA[ The FDA recently approved the use of Menactra (meningococcal conjugate vaccine) to prevent meningococcal disease in infants and toddlers aged 9 to 23 months. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4244/Menactra/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4244/Menactra/</guid>
</item>

<item>
<pubDate>Wed, 20 Apr 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for TNF Blockers, Azathioprine, Mercaptopurine</title>
<description><![CDATA[ The FDA recently reported cases of hepatosplenic T-cell lymphoma (HSTCL) seen in adolescents and young adults being treated with immunosuppressant drugs, specifically tumor necrosis factor (TNF) blockers (Cimzia, Enbrel, Humira, Remicade, and Simponi), azathioprine, and/or mercaptopurine, either in combination or alone.  Most patients were being treated for Crohns disease or ulcerative colitis, but HSTCL has also been reported in patients receiving these drugs for psoriasis and rheumatoid arthritis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2021/mercaptopurine/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2021/mercaptopurine/</guid>
</item>

<item>
<pubDate>Wed, 13 Apr 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Benzocaine</title>
<description><![CDATA[ The FDA recently updated their recommendations regarding the risk of methemoglobinemia associated with products containing benzocaine.  Methemoglobinemia has been reported with all strengths and forms of benzocaine, including over-the-counter gels and liquids and sprays used for medical procedures.  Most cases have occurred in young children, prompting the recommendation that benzocaine products should not be used on children less than two years of age, except under the advice and supervision of a healthcare professional. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1ba3961/Orajel/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1ba3961/Orajel/</guid>
</item>

<item>
<pubDate>Wed, 6 Apr 2011 08:00:00 GMT</pubDate>
<title>Zostavax Approved to Prevent Shingles in a Younger Population</title>
<description><![CDATA[ The FDA recently approved Zostavax (zoster vaccine, live) for patients 50 to 59 years of age, adding to the previously-approved population of 60 years of age and older.  Approximately 200,000 healthy people between 50 and 59 are affected by shingles each year.  Compared to placebo, Zostavax reduced the risk of developing shingles in this age group by approximately 70 percent. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4373/Zostavax/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4373/Zostavax/</guid>
</item>

<item>
<pubDate>Wed, 31 Mar 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Benlysta</title>
<description><![CDATA[ The FDA recently approved the monoclonal antibody Benlysta (belimumab) to treat active, autoantibody-positive lupus.  The drug inhibits B-lymphocyte stimulator (BLyS) protein, thereby inhibiting B-cell survival, including autoreactive B cells. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1016017/Benlysta/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1016017/Benlysta/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 31 Mar 2011 08:00:00 GMT</pubDate>
<title>New Generic Drug Monograph for Docetaxel</title>
<description><![CDATA[ The FDA recently approved the taxane mitosis inhibitor docetaxel (first-time generic for Taxotere) to treat patients at specific stages of five types of cancer: metastatic and adjuvant breast cancer, metastatic androgen-independent prostate cancer, advanced non-small cell lung cancer, advanced gastric adenocarcinoma, and locally advanced squamous cell carcinoma of the head and neck. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1011636/docetaxel/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1011636/docetaxel/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 23 Mar 2011 08:00:00 GMT</pubDate>
<title>MedWatch Labeling Change for Fluoroquinolones</title>
<description><![CDATA[ The FDA recently announced labeling changes for the fluoroquinolone class of antibiotics, including Avelox (moxifloxacin), Cipro and Proquin XR (ciprofloxacin), Factive (gemifloxacin), Floxin (ofloxacin), Levaquin (levofloxacin), and Noroxin (norfloxacin).  New safety information has been included regarding the neuromuscular blocking activity of fluoroquinolones and the risk of exacerbation in patients with a history of myasthenia gravis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b502/ciprofloxacin/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b502/ciprofloxacin/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 16 Mar 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Kaletra</title>
<description><![CDATA[ The FDA recently issued a warning about the use of the combination protease inhibitor Kaletra (lopinavir/ritonavir) in premature infants and neonates.  The oral solution of Kaletra contains alcohol and propylene glycol, which can lead to serious heart, kidney, or breathing problems in infants who are unable to effectively eliminate these ingredients.  The oral solution should be avoided in premature infants until 14 days after their due date and in full-term infants younger than 14 days of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10c2334/Kaletra/Safety+Monitoring/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10c2334/Kaletra/Safety+Monitoring/</guid>
</item>

<item>
<pubDate>Wed, 9 Mar 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Proton Pump Inhibitors</title>
<description><![CDATA[ The FDA recently issued a safety communication for the entire class of proton pump inhibitors (PPIs) relating to the risk of developing hypomagnesemia with long-term use.  Hypomagnesemia can result in tetany, arrhythmias, and seizures.  Serum magnesium levels should be considered for patients expected to be on PPIs for long periods of time, especially those taking digoxin, diuretics, or drugs that may cause hypomagnesemia. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10c1131/omeprazole/Safety+Monitoring/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10c1131/omeprazole/Safety+Monitoring/</guid>
</item>

<item>
<pubDate>Wed, 2 Mar 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Antipsychotic Drugs</title>
<description><![CDATA[ The FDA recently announced labeling changes for the entire class of antipsychotic drugs relating to their use during the third trimester of pregnancy and the potential risk for extrapyramidal signs (EPS) and withdrawal symptoms in newborns.  Symptoms of EPS and withdrawal in newborns may include agitation, changes in muscle tone, tremor, sleepiness, severe difficulty breathing, and difficulty in feeding. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1051199/risperidone/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1051199/risperidone/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 23 Feb 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Terbutaline</title>
<description><![CDATA[ The FDA recently warned healthcare professionals against prolonged use of injectable terbutaline (greater than 48-72 hours) for the prevention or treatment of preterm labor.  They add that oral terbutaline has not shown efficacy and should not be used for this indication.  Prolonged administration of terbutaline in pregnant women may increase the risk of serious adverse reactions, including tachycardia, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, myocardial ischemia, and death. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b456/terbutaline/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b456/terbutaline/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 16 Feb 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Latuda</title>
<description><![CDATA[ The FDA recently approved the second generation antipsychotic Latuda (lurasidone) for the treatment of schizophrenia in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5989/Latuda/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5989/Latuda/</guid>
</item>

<item>
<pubDate>Wed, 09 Feb 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Rosiglitazone</title>
<description><![CDATA[ The FDA recently announced further updates to the labels for Avandia (rosiglitazone), Avandamet (rosiglitazone/metformin), and Avandaryl (rosiglitazone/glimepiride) relating to the cardiovascular risks, including myocardial infarction, associated with the diabetes drug rosiglitazone.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b2049/Avandia/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b2049/Avandia/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 26 Jan 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Kapvay</title>
<description><![CDATA[ The FDA recently approved Kapvay (clonidine) to treat attention deficit hyperactivity disorder (ADHD) in pediatric patients 6-17 years old.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5979/Kapvay/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5979/Kapvay/</guid>
</item>

<item>
<pubDate>Wed, 19 Jan 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Multaq</title>
<description><![CDATA[ The FDA recently notified healthcare professionals about cases of rare, but severe liver injury reported in patients receiving the oral antiarrhythmia drug Multaq (dronedarone).  Healthcare professionals should consider obtaining hepatic liver enzymes periodically, especially during the first 6 months of treatment.  Patients should be advised to report  any signs and symptoms, such as anorexia, nausea, vomiting, fever, malaise, fatigue, right upper quadrant pain, jaundice, dark urine, or itching while taking Multaq.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5435/Multaq/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5435/Multaq/</guid>
</item>

<item>
<pubDate>Wed, 12 Jan 2011 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Morphine Sulfate</title>
<description><![CDATA[ The FDA recently notified healthcare professionals about serious adverse events and deaths from accidental overdose of concentrated oral morphine sulfate solutions.  The product labeling and packaging will be revised to differentiate the concentrated (100 mg per 5 mL) solutions from other solutions (10 mg per 5 mL and 20 mg per 5 mL) to help prevent future medication errors.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b111/morphine+sulfate/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b111/morphine+sulfate/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 05 Jan 2011 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Teflaro</title>
<description><![CDATA[ The FDA recently approved the first 5th generation cephalosporin Teflaro (ceftaroline) for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, including methicillin-resistant Staphylococcus aureus (MRSA).  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5967/Teflaro/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5967/Teflaro/</guid>
</item>

<item>
<pubDate>Wed, 22 Dec 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Anzemet</title>
<description><![CDATA[ The FDA recently notified healthcare professionals about the risk of developing potentially fatal torsade de pointes from the antiemetic drug Anzemet (dolasetron).  Anzemet causes dose-dependent prolongation of the QT, PR, and QRS intervals, and should not be used in patients with congenital long-QT syndrome.  Hypokalemia and hypomagnesemia should be corrected before administering Anzemet.  Patients with congestive heart failure, bradycardia, underlying heart disease, or who are elderly or renally impaired should receive ECG monitoring while taking Anzemet.  The injectable form is no longer recommended for the treatment of chemotherapy induced nausea and vomiting (CINV), but may still be used for postoperative nausea and vomiting because lower doses are given.  Anzemet tablets may still be used for CINV, since they are associated with less risk of abnormal heart rhythm.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a398/Anzemet/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a398/Anzemet/</guid>
</item>

<item>
<pubDate>Wed, 15 Dec 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Atelvia</title>
<description><![CDATA[ The FDA recently approved the delayed-release bisphosphonate Atelvia (risedronate) for the treatment of postmenopausal osteoporosis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5961/Atelvia/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5961/Atelvia/</guid>
</item>

<item>
<pubDate>Wed, 01 Dec 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Ella</title>
<description><![CDATA[ The FDA recently approved the progesterone agonist/antagonist Ella (ulipristal) for emergency contraception within 120 hours of unprotected intercourse. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5952/Ella/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5952/Ella/</guid>
</item>

<item>
<pubDate>Wed, 23 Nov 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Halaven</title>
<description><![CDATA[ The FDA recently approved the microtubule inhibitor Halaven (eribulin) for the treatment of metastatic breast cancer in adult patients who have previously received at least two chemotherapeutic regimens that included an anthracycline and a taxane. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5947/Halaven/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5947/Halaven/</guid>
</item>

<item>
<pubDate>Wed, 17 Nov 2010 08:00:00 GMT</pubDate>
<title>New Indication for Vyvanse</title>
<description><![CDATA[ The FDA recently approved Vyvanse (lisdexamfetamine) to treat adolescents (13-17 years old) with attention deficit hyperactivity disorder (ADHD).  Vyvanse is already indicated to treat children 6-12 years old and adult patients with ADHD. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1024679/Vyvanse/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1024679/Vyvanse/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 10 Nov 2010 08:00:00 GMT</pubDate>
<title>New Indication for Cymbalta</title>
<description><![CDATA[ The FDA recently approved a new indication for the serotonin- norepinephrine reuptake inhibitor (SNRI), Cymbalta (duloxetine).  In addition to treating major depressive disorder, diabetic neuropathy, generalized anxiety disorder, and fibromyalgia, Cymbalta is now indicated to treat chronic musculoskeletal pain in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1013747/Cymbalta/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1013747/Cymbalta/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 03 Nov 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Pradaxa</title>
<description><![CDATA[ The FDA recently approved the oral thrombin inhibitor Pradaxa (dabigatran) to prevent thromboembolic events in adult patients with atrial fibrillation. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5941/Pradaxa/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5941/Pradaxa/</guid>
</item>

<item>
<pubDate>Wed, 27 Oct 2010 08:00:00 GMT</pubDate>
<title>New Indication for Botox</title>
<description><![CDATA[ The FDA recently approved the use of Botox (onabotulinumtoxinA) for the prophylaxis of headaches in adult patients with chronic migraine. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1013450/Botox/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1013450/Botox/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 20 Oct 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Bisphosphonates</title>
<description><![CDATA[ The FDA recently advised of atypical subtrochanteric and diaphyseal femur fractures reported in patients taking bisphosphonates for osteoporosis, including Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast (and their generic products).  The FDA recommends patients should continue taking bisphosphonates, but those with evidence of femoral shaft fractures should discontinue taking bisphosphonates and any other potent antiresorptive medications. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/105769/alendronate/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/105769/alendronate/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 13 Oct 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Gilenya</title>
<description><![CDATA[ The FDA recently approved the sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adults with relapsing forms of multiple sclerosis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5885/Gilenya/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5885/Gilenya/</guid>
</item>

<item>
<pubDate>Wed, 06 Oct 2010 08:00:00 GMT</pubDate>
<title>New Indication for Ozurdex</title>
<description><![CDATA[ The FDA recently approved a new use for the ophthalmic corticosteroid Ozurdex (dexamethasone intravitreal implant).  In addition to macular edema, the drug is now indicated for posterior uveitis in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015488/Ozurdex/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015488/Ozurdex/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 29 Sep 2010 08:00:00 GMT</pubDate>
<title>New Dosing for Faslodex</title>
<description><![CDATA[ The FDA recently approved a new dosing regimen for Faslodex (fulvestrant) based on data from CONFIRM (Comparison of Faslodex In Recurrent or Metastatic breast cancer) that demonstrated a reduction in the risk of disease progression with 500 mg vs. 250 mg dosing. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1012712/Faslodex/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1012712/Faslodex/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 22 Sep 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Valcyte</title>
<description><![CDATA[ The FDA recently announced new pediatric dosing recommendations for the antiviral medication, Valcyte (valganciclovir), to help reduce the potential for overdosing children with low body weight, low body surface area, and below normal serum creatinine.  The new recommendation adds an upper limit of 150 mL/min/1.73 m2 to the creatinine clearance calculated using the Schwartz formula for the determination of pediatric doses. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022521/Valcyte/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022521/Valcyte/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 15 Sep 2010 08:00:00 GMT</pubDate>
<title>New Indications for Saphris</title>
<description><![CDATA[ The FDA recently approved two new indications for Saphris (asenapine).  In addition to the acute treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar disorder, the drug is now indicated for maintenance treatment of schizophrenia and adjunctive treatment with lithium or valproate for acute manic or mixed episodes of bipolar disorder. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015576/Saphris/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015576/Saphris/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 01 Sep 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Oravig</title>
<description><![CDATA[ The FDA recently approved the azole antifungal agent Oravig (miconazole) to treat oropharyngeal candidiasis in patients greater than 16 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5818/Oravig/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5818/Oravig/</guid>
</item>

<item>
<pubDate>Wed, 25 Aug 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Stalevo</title>
<description><![CDATA[ The FDA recently notified healthcare professionals that patients taking Stalevo (carbidopa/levodopa/entacapone) may be at increased risk for cardiovascular events, compared to patients taking Sinemet (carbidopa/levodopa).  Patients taking Stalevo should have their cardiovascular status regularly evaluated, especially if they have a history of cardiovascular disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1033519/Stalevo/Contraindications+Cautions/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1033519/Stalevo/Contraindications+Cautions/</guid>
</item>

<item>
<pubDate>Wed, 18 Aug 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Lamictal</title>
<description><![CDATA[ The product labeling for Lamictal (lamotrigine) has been revised to include information about aseptic meningitis associated with the use of the drug.  Lamictal is commonly used to treat seizures in children and adults and bipolar disorder in adults.  Patients being treated with Lamictal should be monitored for symptoms of meningitis, including headache, fever, stiff neck, nausea, vomiting, rash, and sensitivity to light. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/105850/Lamictal/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/105850/Lamictal/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 11 Aug 2010 08:00:00 GMT</pubDate>
<title>Influenza Vaccine Updates</title>
<description><![CDATA[ Based on the CDC’s Advisory Committee on Immunization Practices (ACIP) recommendations for the 2010-11 season, the influenza vaccine monographs for Afluria, Agriflu, Fluarix, FluLaval, FluMist, Fluvirin, Fluzone, and Fluzone High-Dose, as well as the adult and pediatric vaccination tables, have been updated.  The ACIP is recommending that all persons aged greater than or equal to 6 months be vaccinated; children between 6 months and 8 years who were inadequately vaccinated for the seasonal or H1N1 influenza in 2009-10 should receive 2 doses of the influenza vaccine in 2010-11; and trivalent vaccines containing A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens should be used. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a3465/Fluzone/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a3465/Fluzone/</guid>
</item>

<item>
<pubDate>Wed, 04 Aug 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Cubicin</title>
<description><![CDATA[ The FDA recently issued a communication about the risk of eosinophilic pneumonia associated with Cubicin (daptomycin), based on post-marketing adverse event reports.  Patients being treated with Cubicin should be closely monitored for symptoms, which may include fever, cough, shortness of breath, and difficulty breathing. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1053565/Cubicin/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1053565/Cubicin/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 28 Jul 2010 08:00:00 GMT</pubDate>
<title>New First-Time Generic for Enoxaparin</title>
<description><![CDATA[ The FDA recently approved the first generic low molecular weight heparin enoxaparin (generic for Lovenox) for the prophylaxis and treatment of deep vein thrombosis, the prophylaxis of ischemic complications related to unstable angina and non-Q-wave myocardial infarction, and the treatment of acute ST-elevation myocardial infarction in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1701/enoxaparin/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1701/enoxaparin/</guid>
</item>

<item>
<pubDate>Wed, 21 Jul 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Arava</title>
<description><![CDATA[ The FDA recently announced a new boxed warning for the risk of severe liver injury associated with Arava (leflunomide), a disease-modifying antirheumatic drug (DMARD) used to treat rheumatoid arthritis in adult patients.  The decision to add the boxed warning is based on adverse event reports of severe liver injury, including fatal liver failure.  To reduce this risk it is recommended that patients should not receive the drug if they have pre-existing liver disease or ALT greater than two times the upper limit of normal.  Caution should be exercised when patients are taking other hepatotoxic drugs in combination with leflunomide.  Liver enzymes should be monitored and therapy discontinued if the ALT rises to greater than two times the upper limit of normal. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b2061/Arava/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b2061/Arava/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 14 Jul 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Jevtana</title>
<description><![CDATA[ The FDA recently approved the taxane antineoplastic agent Jevtana (cabazitaxel) for patients with hormone-refractory metastatic prostate cancer who have been previously treated with docetaxel. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015768/Jevtana/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015768/Jevtana/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 07 Jul 2010 08:00:00 GMT</pubDate>
<title>New Generic Drug Monograph for Aztreonam</title>
<description><![CDATA[ The FDA recently approved the first-time generic aztreonam (Azactam), a monobactam antibiotic for the treatment of infections caused by susceptible gram-negative organisms in adult and pediatric patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1486/aztreonam/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1486/aztreonam/</guid>
</item>

<item>
<pubDate>Wed, 30 Jun 2010 08:00:00 GMT</pubDate>
<title>New First-Time Generic for Meropenem</title>
<description><![CDATA[ The FDA recently approved the carbapenem antibiotic meropenem (generic for Merrem) for the treatment of skin and skin structure, intra-abdominal, and bacterial meningitis infections caused by susceptible organisms in adult and pediatric patients greater than three months old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1576/meropenem/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1576/meropenem/</guid>
</item>

<item>
<pubDate>Wed, 23 Jun 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Lysteda</title>
<description><![CDATA[ The FDA recently approved the oral non-hormonal therapy, Lysteda (tranexamic acid), for the treatment of menorrhagia in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5750/Lysteda/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5750/Lysteda/</guid>
</item>

<item>
<pubDate>Wed, 16 Jun 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Prolia</title>
<description><![CDATA[ The FDA recently approved the receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor, Prolia (denosumab).  This injectable drug is given every six months for the treatment of osteoporosis in postmenopausal patients with a history of osteoporotic fracture, multiple fracture risk factors, or who have failed or are intolerant to other osteoporosis treatments. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5749/Prolia/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5749/Prolia/</guid>
</item>

<item>
<pubDate>Wed, 09 Jun 2010 08:00:00 GMT</pubDate>
<title>New Generic Drug Monograph for Adapalene</title>
<description><![CDATA[ The FDA recently approved the first-time generic adapalene topical (Differin Gel), a retinoid for the treatment of acne in adults and children greater than 12 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1784/adapalene+topical/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1784/adapalene+topical/</guid>
</item>

<item>
<pubDate>Wed, 02 Jun 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Tramadol Products</title>
<description><![CDATA[ The FDA announced strengthened warnings for products containing the centrally-acting synthetic opioid analgesic, tramadol (Ultram, Ultram ER, Ultracet, Ryzolt, and generic formulations), which are indicated for moderate to moderately-severe chronic pain.  There is an increased risk of suicide for patients with a history of emotional disturbances or suicidal ideation or attempts, as well as histories of addiction or misuse of tranquilizers, alcohol, and other CNS-active drugs.  Tramadol has additive effects when used in conjunction with other CNS depressants, and overdosage can result in CNS depression, respiratory depression, and death.  Tramadol has mu-opioid agonist activity, and may be subject to misuse, abuse, or criminal diversion. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1348/Ultram/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1348/Ultram/</guid>
</item>

<item>
<pubDate>Wed, 26 May 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Cambia</title>
<description><![CDATA[ The FDA recently approved the non-steroidal anti-inflammatory drug Cambia (diclofenac potassium) for the acute treatment of migraine headache in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015719/Cambia/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015719/Cambia/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 12 May 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Zirgan</title>
<description><![CDATA[ The FDA recently approved the antiviral medication Zirgan (ganciclovir ophthalmic) for the treatment of acute herpetic keratitis (dendritic ulcers) in adult and pediatric patients greater than two years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5718/Zirgan/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5718/Zirgan/</guid>
</item>

<item>
<pubDate>Wed, 05 May 2010 08:00:00 GMT</pubDate>
<title>New Generic Extended-Release Formulation for Amoxicillin/Clavulanate</title>
<description><![CDATA[ The FDA recently approved the generic extended-release formulation of amoxicillin/clavulanate (Augmentin XR) for the treatment of community-acquired pneumonia and acute bacterial sinusitis in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/101420/amoxicillin-clavulanate/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/101420/amoxicillin-clavulanate/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 27 Apr 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Propylthiouracil</title>
<description><![CDATA[ A new boxed warning has been added to the prescribing information for the hyperthyroidism medication propylthiouracil (PTU).  Serious liver injury, including liver failure and death, has been associated with the use of PTU.  The FDA recommends that PTU be reserved for patients who are unable to take methimazole due to allergy, intolerance, or during the first trimester of pregnancy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b278/propylthiouracil/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b278/propylthiouracil/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 21 Apr 2010 08:00:00 GMT</pubDate>
<title>New Drug Monographs for Losartan and Losartan/Hydrochlorothiazide</title>
<description><![CDATA[ The FDA recently approved first-time generic formulations of Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) for the treatment of hypertension, diabetic nephropathy, and stroke prevention. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a551/losartan/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a551/losartan/</guid>
</item>

<item>
<pubDate>Wed, 14 Apr 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Exalgo</title>
<description><![CDATA[ The FDA recently approved Exalgo (hydromorphone), a once daily extended-release tablet for the treatment of moderate to severe chronic pain in opioid tolerant adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5686/Exalgo/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5686/Exalgo/</guid>
</item>

<item>
<pubDate>Wed, 07 Apr 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Qutenza</title>
<description><![CDATA[ The FDA recently approved Qutenza (capsaicin topical) for the localized treatment of post-herpetic neuralgia in adult patients.  The patch must be administered by a healthcare professional and may be repeated every three months. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5685/Qutenza/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5685/Qutenza/</guid>
</item>

<item>
<pubDate>Wed, 31 Mar 2010 08:00:00 GMT</pubDate>
<title>New Indication for Crestor</title>
<description><![CDATA[ The FDA recently approved a new indication for Crestor (rosuvastatin) as primary prevention of cardiovascular disease in patients without clinically evident coronary heart disease.  Patients should be at increased risk for cardiovascular disease based on age (men greater than 50 years old and women greater than 60 years old), elevated high-sensitivity C-reactive protein, and the presence of at least one additional risk factor, such as hypertension, low HDL-C, smoking, or family history of premature heart disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1013477/Crestor/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1013477/Crestor/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 24 Mar 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Zyprexa Relprevv</title>
<description><![CDATA[ The FDA recently approved the extended-release intramuscular suspension of the second generation antipsychotic, Zyprexa Relprevv (olanzapine), for the treatment of schizophrenia in adults.  This formulation can be administered every two to four weeks, depending on the dose. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015673/Zyprexa+Relprevv/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015673/Zyprexa+Relprevv/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 17 Mar 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Plavix</title>
<description><![CDATA[ A new boxed warning has been added to the prescribing information for the antiplatelet drug Plavix (clopidogrel).  Plavix is metabolized to its active form by the cytochrome P450 (CYP) system, principally CYP2C19.  Less active metabolite is formed and a smaller antiplatelet effect is observed in poor CYP2C19 metabolizers.  Tests are available to identify genetic differences in CYP2C19 function.  Healthcare professionals should consider alternative dosing strategies or other antiplatelet medications in patients identified as poor metabolizers. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b1113/Plavix/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b1113/Plavix/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 10 Mar 2010 08:00:00 GMT</pubDate>
<title>Name Change for Kapidex</title>
<description><![CDATA[ Starting in April 2010, the proton pump inhibitor Kapidex (dexlansoprazole) will be marketed under the new name Dexilant to avoid confusion and dispensing errors with two other medications, Casodex (bicalutamide) and Kadian (morphine sulfate). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1014917/Dexilant/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1014917/Dexilant/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 03 Mar 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Invirase</title>
<description><![CDATA[ Based on an on-going review of clinical trial data, the FDA is notifying healthcare professionals about possible QT and PR prolongation associated with the combination of Invirase (saquinavir) and Norvir (ritonavir).  Invirase and Norvir should not be used in patients already taking medications known to cause QT prolongation or in patients with a history of QT prolongation, preexisting conduction system disease, ischemic heart disease, cardiomyopathy, or underlying structural heart disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a830/Invirase/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a830/Invirase/</guid>
</item>

<item>
<pubDate>Wed, 24 Feb 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Long-Acting Beta-Agonists</title>
<description><![CDATA[ The FDA is issuing new safe use requirements for all long-acting beta-agonists (LABAs) used to treat asthma, including Foradil Aerolizer (formoterol) and Serevent Diskus (salmeterol), based on an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization and death in some adult and pediatric patients.  LABAs should only be used in combination therapy for patients whose asthma cannot be adequately controlled on asthma controller medications.  LABAs should be used for the shortest duration of time and discontinued, if possible, once asthma control is achieved.  It is recommended that pediatric and adolescent patients who require the addition of a LABA to an inhaled corticosteroid use a combination product to improve compliance. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2468/Serevent+Diskus/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2468/Serevent+Diskus/</guid>
</item>

<item>
<pubDate>Wed, 17 Feb 2010 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for Benicar</title>
<description><![CDATA[ The FDA recently approved the angiotensin II receptor blocker (ARB) Benicar (olmesartan) for the treatment of pediatric hypertension in patients 6-16 years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4015/Tysabri/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022720/Benicar/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 10 Feb 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Tysabri</title>
<description><![CDATA[ The FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) associated with Tysabri (natalizumab),  an immunosuppressant used to treat relapsing forms of multiple sclerosis and moderate to severe Crohn’s disease.  The risk of PML increases with the number of Tysabri infusions received.  Patients who have developed PML and subsequently discontinued Tysabri may also develop immune reconstitution inflammatory syndrome (IRIS), a rare condition characterized by a severe inflammatory response that can occur during or following immune system recovery, causing an unexpected decline in a patient’s condition after return of immune function. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4015/Tysabri/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4015/Tysabri/</guid>
</item>

<item>
<pubDate>Wed, 03 Feb 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Didanosine</title>
<description><![CDATA[ The FDA notified healthcare professionals about non-cirrhotic portal hypertension in patients using Videx or Videx EC (didanosine), a nucleoside reverse transcriptase inhibitor for treating HIV.  Although rare, portal hypertension can cause serious complications, including death from hemorrhaging esophageal varices.  The FDA believes the clinical benefits outweigh the potential risks for certain patients, and the decision to use this drug must be made on an individual basis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1051396/didanosine/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1051396/didanosine/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 27 Jan 2010 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Meridia</title>
<description><![CDATA[ Based on data that indicate an increased risk of heart attack and stroke in patients with a history of cardiovascular disease using Meridia (sibutramine), the FDA requested and the manufacturer agreed to add a new contraindication to the Meridia drug label.  Meridia is not to be used in patients with a history of cardiovascular disease, including coronary artery disease, history of stroke or transient ischemic attack, history of arrhythmias, history of congestive heart failure, history of peripheral arterial disease, or uncontrolled hypertension. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/103952/Meridia/Contraindications+Cautions/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/103952/Meridia/Contraindications+Cautions/</guid>
</item>

<item>
<pubDate>Wed, 20 Jan 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Fanapt</title>
<description><![CDATA[ The FDA recently approved the atypical antipsychotic Fanapt (iloperidone) for the treatment of schizophrenia adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015612/Fanapt/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015612/Fanapt/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 06 Jan 2010 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Sumavel DosePro</title>
<description><![CDATA[ The FDA recently approved a needle-free subcutaneous delivery system, Sumavel DosePro (sumatriptan), for acute migraine and cluster headache symptoms in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1015607/Sumavel+DosePro/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1015607/Sumavel+DosePro/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 30 Dec 2009 08:00:00 GMT</pubDate>
<title>New Boxed Warning for Phenergan</title>
<description><![CDATA[ A new boxed warning was recently added to Phenergan (promethazine) describing the risks of severe tissue injury, including gangrene requiring amputation, resulting from intravenous injection.  Healthcare practitioners are reminded that the preferred route of administration is deep intramuscular injection and that subcutaneous injection is contraindicated. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b1110/Phenergan/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b1110/Phenergan/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 23 Dec 2009 08:00:00 GMT</pubDate>
<title>New Indication for Seroquel XR</title>
<description><![CDATA[ The FDA recently approved Seroquel XR (quetiapine) as adjunctive treatment to antidepressants for major depressive disorder in adults. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1014683/Seroquel+XR/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1014683/Seroquel+XR/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 16 Dec 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Valproate Products</title>
<description><![CDATA[ The FDA recently notified healthcare professionals and patients about the increased risk of birth defects in babies exposed to divalproex sodium, valproate sodium, or valproic acid during pregnancy.  Reported birth defects include neural tube defects, craniofacial defects, and cardiovascular malformations.  Women of childbearing potential should be informed of the risks, use effective contraception, and consider other options when appropriate.  Pregnant women using valproate or other AEDs should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry (1-888-233-2334; www.aedpregnancyregistry.org). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a304/valproic+acid/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a304/valproic+acid/</guid>
</item>

<item>
<pubDate>Wed, 02 Dec 2009 08:00:00 GMT</pubDate>
<title>New Pediatric Indication Approved for Abilify</title>
<description><![CDATA[ The FDA recently approved Abilify (aripiprazole) for use in patients 6 to 17 years of age to treat irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1023259/Abilify/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1023259/Abilify/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 25 Nov 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Local Anesthetics</title>
<description><![CDATA[ The FDA recently notified healthcare professionals of the risk of chondrolysis in patients given continuous intra-articular infusions of local anesthetics with elastomeric infusion devices to control post-surgical pain.  Patients reported joint pain, stiffness, and loss of motion as early as two months after receiving the infusions.  More than half of the patients required additional surgery, including arthroscopy or arthroplasty, due to cartilage destruction or atrophy.  Healthcare professionals are cautioned to avoid using local anesthetics via continuous intra-articular postoperative infusions. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/103316/lidocaine/Contraindications+Cautions/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/103316/lidocaine/Contraindications+Cautions/</guid>
</item>

<item>
<pubDate>Wed, 18 Nov 2009 08:00:00 GMT</pubDate>
<title>New Pediatric Indications for Two Influenza Vaccines</title>
<description><![CDATA[ The FDA recently approved Afluria (influenza A and B (seasonal flu) vaccine) and Influenza A H1N1 2009 Vaccine (CSL) for use in children greater than 6 months of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1024696/Afluria/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1024696/Afluria/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 11 Nov 2009 08:00:00 GMT</pubDate>
<title>FDA Update - Tamiflu Use in Pediatrics</title>
<description><![CDATA[ The FDA recently amended the Emergency Use Authorization (EUA) for Tamiflu (oseltamivir) in infants less than 1 year of age for the treatment and prophylaxis of influenza A 2009 H1N1 virus.  Treatment doses should be based on weight rather than age, whenever possible.  Prophylaxis is not recommended for infants less than 3 months old, due to limited data on use in this age group, unless the exposure is significant and the risk of severe illness is considered high.  Tamiflu should be used only in full-term infants, since there are insufficient data to recommend a specific dose for premature infants. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022172/Tamiflu/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022172/Tamiflu/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 04 Nov 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Byetta</title>
<description><![CDATA[ The FDA notified healthcare professionals about reports of acute renal failure and insufficiency associated with the use of Byetta (exenatide), an incretin mimetic drug used for type 2 diabetes mellitus.  It is recommended that Byetta should not be used in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease.  Caution is advised when initiating therapy or increasing the dose from 5 to 10 mcg in patients with moderate renal impairment (creatinine clearance 30-50 mL/min).  All patients receiving Byetta should be carefully monitored for the development of kidney dysfunction. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4155/Byetta/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4155/Byetta/</guid>
</item>

<item>
<pubDate>Wed, 28 Oct 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Peramivir</title>
<description><![CDATA[ The FDA issued an emergency use authorization (EUA) for the investigational intravenous neuraminidase inhibitor, peramivir, for use in children and adults with known or suspected infection with influenza A 2009 H1N1 virus.  This unapproved product should be used only for hospitalized patients who are unresponsive to or unable to take oral or inhaled antiviral therapies, or when IV therapy is deemed clinically appropriate. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5584/peramivir/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5584/peramivir/</guid>
</item>

<item>
<pubDate>Wed, 21 Oct 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Folotyn</title>
<description><![CDATA[ The new folate antagonist, Folotyn (pralatrexate), was recently approved for adult patients with relapsed or refractory peripheral T-cell lymphoma. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5580/Folotyn/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5580/Folotyn/</guid>
</item>

<item>
<pubDate>Wed, 14 Oct 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Relenza</title>
<description><![CDATA[ The FDA notified healthcare professionals that Relenza (zanamivir) is intended for use only with the Diskhaler device provided with the drug product.  The powder should not be removed from its packaging or reconstituted in liquid formulations for use in any nebulizer or mechanical ventilator.  The safety, efficacy, and stability of Relenza via nebulizer has not been established.  Additionally, nebulized formulations can obstruct proper functioning of mechanical ventilator equipment, posing a safety risk for patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2077/Relenza/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2077/Relenza/</guid>
</item>

<item>
<pubDate>Wed, 7 Oct 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Heparin</title>
<description><![CDATA[ Effective October 1, 2009, the heparin marketed in the United States will be approximately 10% less potent due to new standardization processes.  This may have clinical relevance in the setting of bolus intravenous dosing when an immediate anticoagulant effect is desired.  Healthcare providers should be aware that increased bolus doses and close monitoring may be required to achieve and maintain anticoagulation in some patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a105/heparin/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a105/heparin/</guid>
</item>

<item>
<pubDate>Wed, 30 Sep 2009 08:00:00 GMT</pubDate>
<title>New Drug Monographs for Influenza A H1N1 2009 Vaccines</title>
<description><![CDATA[ The FDA recently approved intramuscular and intranasal vaccines for immunization against influenza A H1N1 2009 (swine flu).  Availability of these vaccines is anticipated in the next few weeks. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5548/Influenza+A+H1N1+2009+Vaccine+(sanofi+pasteur)/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5548/Influenza+A+H1N1+2009+Vaccine+(sanofi+pasteur)/</guid>
</item>

<item>
<pubDate>Wed, 23 Sep 2009 08:00:00 GMT</pubDate>
<title>MedWatch Update for Tasigna</title>
<description><![CDATA[ Exposure to the tyrosine kinase inhibitor, Tasigna (nilotinib), is increased in patients with hepatic impairment.  Specific dose reductions have been recommended for patients with mild to severe hepatic impairment, and the QT interval should be monitored closely in these patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4785/Tasigna/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4785/Tasigna/</guid>
</item>

<item>
<pubDate>Wed, 16 Sep 2009 08:00:00 GMT</pubDate>
<title>New Monograph for Invega Sustenna</title>
<description><![CDATA[ The FDA recently approved an intramuscular formulation of the second-generation antipsychotic, Invega Sustenna (paliperidone palmitate) for adult patients with schizophrenia. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5528/Invega+Sustenna/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5528/Invega+Sustenna/</guid>
</item>

<item>
<pubDate>Wed, 9 Sep 2009 08:00:00 GMT</pubDate>
<title>New Monograph and MedWatch Safety Alert for Colcrys</title>
<description><![CDATA[ The first FDA-approved single-ingredient oral colchicine product, Colcrys, was recently approved for the treatment of acute gout and familial Mediterranean fever in adults and children over 4 years old.  Oral colchicine has been used for many years as an unapproved drug without FDA-approved prescribing information, dosage recommendations, or drug-interaction warnings.  Based on adverse drug reports, published literature, and pharmacokinetic and drug interaction studies, the FDA analysis revealed that a substantially lower dose of colchicine was as effective, with significantly fewer adverse events, compared to the higher dose traditionally used to treat acute gout flares. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5466/Colcrys/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5466/Colcrys/</guid>
</item>

<item>
<pubDate>Wed, 2 Sep 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Intelence</title>
<description><![CDATA[ There have been post-marketing reports of Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme associated with the use of the non-nucleoside reverse transcriptase inhibitor Intelence (etravirine).  These hypersensitivity reactions have sometimes been complicated by organ dysfunction, including hepatic failure.  The FDA recommends that Intelence therapy be immediately discontinued and liver function tests be monitored when signs and symptoms of severe skin or hypersensitivity reactions develop. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4804/Intelence/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4804/Intelence/</guid>
</item>

<item>
<pubDate>Wed, 26 Aug 2009 08:00:00 GMT</pubDate>
<title>New Indication for Avastin</title>
<description><![CDATA[ The vascular endothelial growth factor (VEGF) inhibitor, Avastin (bevacizumab), was recently approved for use in patients with metastatic renal cell carcinoma, adding to its indications for metastatic breast cancer, metastatic colorectal cancer, progressive glioblastoma, and non-squamous non-small cell lung cancer. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1013620/Avastin/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1013620/Avastin/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 19 Aug 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Multaq</title>
<description><![CDATA[ The FDA recently approved the antiarrhythmic drug Multaq (dronedarone) for adult patients with atrial fibrillation/flutter. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5435/Multaq/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5435/Multaq/</guid>
</item>

<item>
<pubDate>Wed, 12 Aug 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Effient</title>
<description><![CDATA[ The FDA recently approved the platelet aggregation inhibitor Effient (prasugrel) in adult patients with acute coronary syndrome being managed with percutaneous coronary intervention (PCI). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5433/Effient/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5433/Effient/</guid>
</item>

<item>
<pubDate>Wed, 5 Aug 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Botulinum Toxin Products</title>
<description><![CDATA[ The FDA, along with the United States Adopted Names Council (USAN), has revised the generic names for botulinum toxin products to reinforce the understanding that each product has an individual potency and is not interchangeable with any other product.  The new generic names are onabotulinumtoxinA (marketed as Botox/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10c3450/Botox/Safety+Monitoring/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10c3450/Botox/Safety+Monitoring/</guid>
</item>

<item>
<pubDate>Wed, 30 Jul 2009 08:00:00 GMT</pubDate>
<title>Two New Options for Post-Coital Contraception</title>
<description><![CDATA[ The FDA has recently approved two levonorgestrel products for emergency contraception: Plan B One-Step, which is available without a prescription for patients over 17 years old and with a prescription for patients less than 17 (varies by state); and Next Choice, which is available by prescription only for patients less than 17 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2474/Plan+B/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2474/Plan+B/</guid>
</item>

<item>
<pubDate>Wed, 22 Jul 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Leukotriene Inhibitors</title>
<description><![CDATA[ Serious neuropsychiatric events, including agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide), and tremor have been reported in patients taking the leukotriene inhibitors montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo CR).  The FDA recommends that healthcare professionals consider discontinuing these medications if patients develop neuropsychiatric symptoms. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1051239/Singulair/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1051239/Singulair/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 15 Jul 2009 08:00:00 GMT</pubDate>
<title>New Boxed Warning for Smoking Cessation Aids</title>
<description><![CDATA[ The FDA is requiring the manufacturers of varenicline (Chantix) and bupropion (Zyban and generics) to add boxed warnings for the risk of serious neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b4391/Chantix/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b4391/Chantix/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 8 Jul 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Exforge HCT</title>
<description><![CDATA[ The FDA recently approved the first triple combination calcium channel blocker, angiotensin receptor blocker, and diuretic, Exforge HCT (amlodipine/valsartan/hydrochlorothiazide), to treat hypertension in adult patients who have not achieved adequate blood pressure control on dual therapy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5337/Exforge+HCT/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5337/Exforge+HCT/</guid>
</item>

<item>
<pubDate>Wed, 24 Jun 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Nucynta</title>
<description><![CDATA[ Nucynta (tapentadol), an oral mu opioid agonist and norepinephrine reuptake inhibitor, was recently approved for the treatment of acute moderate to severe pain in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a5087/Nucynta/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a5087/Nucynta/</guid>
</item>

<item>
<pubDate>Wed, 17 Jun 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Simponi</title>
<description><![CDATA[ The tumor necrosis factor inhibitor Simponi (golimumab) was recently approved to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4995/Simponi/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4995/Simponi/</guid>
</item>

<item>
<pubDate>Wed, 10 Jun 2009 08:00:00 GMT</pubDate>
<title>New Warning for propylthiouracil</title>
<description><![CDATA[ The FDA recently issued a MedWatch Safety Alert regarding the drug propylthiouracil (PTU) and the risk of serious liver injury, including liver failure and death.  The FDA recommends that PTU be reserved for patients allergic to or intolerant of methimazole, or in their first trimester of pregnancy.  Patients taking PTU should be carefully monitored for signs and symptoms of liver injury, especially in the first six months of therapy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a278/propylthiouracil/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a278/propylthiouracil/</guid>
</item>

<item>
<pubDate>Wed, 03 Jun 2009 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for Axert</title>
<description><![CDATA[ The FDA recently approved Axert (almotriptan) for the treatment of acute migraine in pediatric patients 12-17 years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022594/Axert/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022594/Axert/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 27 May 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Gelnique</title>
<description><![CDATA[ The anticholinergic drug Gelnique (oxybutynin topical) was recently approved to treat symptoms of overactive bladder in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4980/Gelnique/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4980/Gelnique/</guid>
</item>

<item>
<pubDate>Wed, 20 May 2009 08:00:00 GMT</pubDate>
<title>New Boxed Warning for Botulinum Toxin Products</title>
<description><![CDATA[ Manufacturers of botulinum toxin products (Botox, Botox Cosmetic, Myobloc) will be required by the FDA to add a boxed warning about the potential spread of the product beyond the treatment area.  Distant spread of the toxin could result in swallowing and breathing difficulties, including fatal events. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b3450/Botox/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b3450/Botox/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 13 May 2009 08:00:00 GMT</pubDate>
<title>New Boxed Warning for Topical Testosterone Gel Products</title>
<description><![CDATA[ The FDA is requiring a boxed warning in the labeling for the topical testosterone gels AndroGel and Testim due to the risk of secondary exposure.  The boxed warning advises women and children to avoid direct contact with application sites in order to reduce the risk of exposure and subsequent adverse effects. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b2223/AndroGel/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b2223/AndroGel/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 06 May 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Afinitor</title>
<description><![CDATA[ The new oral kinase inhibitor Afinitor (everolimus) was recently launched for the treatment of advanced renal cell cancer in patients refractory to sunitinib or sorafenib therapy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4964/Afinitor/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4964/Afinitor/</guid>
</item>

<item>
<pubDate>Wed, 29 Apr 2009 08:00:00 GMT</pubDate>
<title>Anti-Viral Drug Dosing for Swine Flu</title>
<description><![CDATA[ Based on CDC recommendations, dosing for the prophylaxis and treatment of swine influenza A (H1N1) has been added to the monographs for Tamiflu (oseltamivir) and Relenza (zanamivir). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2172/Tamiflu/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2172/Tamiflu/</guid>
</item>

<item>
<pubDate>Wed, 22 Apr 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Savella</title>
<description><![CDATA[ The new selective serotonin and norepinephrine reuptake inhibitor drug Savella (milnacipran) was recently launched for the treatment of adult patients with fibromyalgia. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4951/Savella/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4951/Savella/</guid>
</item>

<item>
<pubDate>Wed, 15 Apr 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Rapaflo</title>
<description><![CDATA[ The new alpha-blocker drug Rapaflo (silodosin) was recently launched for the treatment of benign prostatic hyperplasia (BPH). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4948/Rapaflo/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4948/Rapaflo/</guid>
</item>

<item>
<pubDate>Wed, 08 Apr 2009 08:00:00 GMT</pubDate>
<title>First-Time Generic Topiramate Now Available</title>
<description><![CDATA[ The generic drug topiramate (brand Topamax) is now available for the treatment of primary generalized tonic-clonic, partial, and Lennox-Gastaut seizures in adults and children over two years old, as well as migraine prophylaxis in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1317/topiramate/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1317/topiramate/</guid>
</item>

<item>
<pubDate>Wed, 01 Apr 2009 08:00:00 GMT</pubDate>
<title>New Indication for Tygacil</title>
<description><![CDATA[ Tygacil (tigecycline), indicated for the treatment of complicated intra-abdominal infections and complicated bacterial skin/skin structure infections, has recently been approved for use in adults with community-acquired pneumonia. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1014152/Tygacil/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1014152/Tygacil/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 25 Mar 2009 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for PEG-Intron and Rebetol Combination Therapy</title>
<description><![CDATA[ The FDA recently approved the combination therapy of PEG-Intron (peginterferon alfa 2b) and Rebetol (ribavirin) therapy to treat chronic hepatitis C infection in pediatric patients greater than 3 years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1022645/PEG-Intron/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1022645/PEG-Intron/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 18 Mar 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Kapidex</title>
<description><![CDATA[ The FDA recently approved the new proton pump inhibitor Kapidex (dexlansoprazole) for the treatment of GERD and erosive esophagitis in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4917/Kapidex/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4917/Kapidex/</guid>
</item>

<item>
<pubDate>Wed, 11 Mar 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Toviaz</title>
<description><![CDATA[ The FDA recently approved the new drug Toviaz (fesoterodine) for the treatment of overactive bladder in adults. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4914/Toviaz/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4914/Toviaz/</guid>
</item>

<item>
<pubDate>Wed, 05 Mar 2009 08:00:00 GMT</pubDate>
<title>New Boxed Warning for Metoclopramide</title>
<description><![CDATA[ The FDA recently issued a MedWatch Safety Alert regarding metoclopramide-containing drugs (Reglan, generics) and the risk of tardive dyskinesia associated with long-term and/or high-dose use. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b255/metoclopramide/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b255/metoclopramide/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 25 Feb 2009 08:00:00 GMT</pubDate>
<title>New Warning for Zonegran</title>
<description><![CDATA[ The FDA recently issued a MedWatch Safety Alert regarding the antiepileptic drug Zonegran (zonisamide) and the risk of metabolic acidosis.  The risk may be higher in younger patients and patients with renal disease, severe respiratory disorders, diarrhea, surgery, ketogenic diet, or concomitant use of other drugs.  The FDA is recommending that prescribers measure serum bicarbonate before therapy is initiated, and periodically during the course of treatment with zonisamide. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2274/Zonegran/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2274/Zonegran/</guid>
</item>

<item>
<pubDate>Wed, 18 Feb 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Vectical</title>
<description><![CDATA[ The FDA recently approved Vectical (calcitriol topical) for the treatment of mild to moderate plaque psoriasis in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4901/Vectical/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4901/Vectical/</guid>
</item>

<item>
<pubDate>Wed, 04 Feb 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Banzel</title>
<description><![CDATA[ The FDA recently approved Banzel (rufinamide) for the adjunct treatment of Lennox-Gastaut seizures in adults and children 4 years and older. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4894/Banzel/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4894/Banzel/</guid>
</item>

<item>
<pubDate>Wed, 28 Jan 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Latisse</title>
<description><![CDATA[ The FDA recently approved the prostaglandin analog Latisse (bimatoprost ophthalmic) for the topical treatment of eyelash hypotrichosis in adults. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4890/Latisse/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4890/Latisse/</guid>
</item>

<item>
<pubDate>Wed, 21 Jan 2009 08:00:00 GMT</pubDate>
<title>First-Time Generic Available for Zerit</title>
<description><![CDATA[ The generic nucleoside reverse transcriptase inhibitor, stavudine, has been recently launched for the treatment of HIV infection in pediatric and adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1431/stavudine/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1431/stavudine/</guid>
</item>

<item>
<pubDate>Wed, 14 Jan 2009 08:00:00 GMT</pubDate>
<title>MedWatch Safety Alert for Innohep</title>
<description><![CDATA[ A controlled clinical study suggests that Innohep (tinzaparin) may increase the risk of death in elderly patients with renal insufficiency compared to unfractionated heparin.  The manufacturer is recommending other alternatives in this patient population when treating deep vein thrombosis, with or without pulmonary embolism. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1012562/Innohep/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1012562/Innohep/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 07 Jan 2009 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Promacta</title>
<description><![CDATA[ The FDA recently approved the oral drug Promacta (eltrombopag) for the treatment of chronic idiopathic thrombocytopenia (ITP) in adults. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4882/Promacta/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4882/Promacta/</guid>
</item>

<item>
<pubDate>Wed, 24 Dec 2008 08:00:00 GMT</pubDate>
<title>First-Time Generic Available for Imitrex</title>
<description><![CDATA[ Generic oral sumatriptan was recently launched for the treatment of acute migraine headache in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1681/sumatriptan/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1681/sumatriptan/</guid>
</item>

<item>
<pubDate>Wed, 17 Dec 2008 08:00:00 GMT</pubDate>
<title>New Black Box Warning for Visicol and OsmoPrep</title>
<description><![CDATA[ The FDA recently released a MedWatch safety summary regarding the risk of acute kidney injury associated with oral sodium phosphate (OSP) products used for bowel cleansing.  The FDA is also recommending that consumers not use over-the-counter laxative OSP products for bowel cleansing. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b4673/Visicol/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b4673/Visicol/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 10 Dec 2008 08:00:00 GMT</pubDate>
<title>FDA Alert for Phenytoin and Fosphenytoin</title>
<description><![CDATA[ New data suggests a possible association between HLA-B*1502 and phenytoin or fosphenytoin-induced serious skin reactions, including Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  Because of the known association between phenytoins and SJS/TEN, healthcare providers should consider avoiding  phenytoin and fosphenytoin as alternatives for carbamazepine in patients who test positive for HLA-B*1502. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1031707/fosphenytoin/Contraindications+Cautions/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1031707/fosphenytoin/Contraindications+Cautions/</guid>
</item>

<item>
<pubDate>Wed, 04 Dec 2008 08:00:00 GMT</pubDate>
<title>New Pediatric Indication for Videx EC</title>
<description><![CDATA[ The FDA recently approved the use of Videx EC (didanosine) for the treatment of HIV in pediatric patients greater than 20 kg. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2455/Videx+EC/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2455/Videx+EC/</guid>
</item>

<item>
<pubDate>Wed, 26 Nov 2008 08:00:00 GMT</pubDate>
<title>Labeling Changes for Ranexa</title>
<description><![CDATA[ The FDA recently approved Ranexa (ranolazine) for the first-line treatment of chronic angina.  This medication may now be used alone or in combination with beta-blockers, calcium channel blockers, and nitrates. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4344/Ranexa/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4344/Ranexa/</guid>
</item>

<item>
<pubDate>Wed, 19 Nov 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Sancuso</title>
<description><![CDATA[ The FDA recently approved Sancuso (granisetron transdermal), a patch for the prevention of chemotherapy-induced nausea and vomiting in adults receiving highly- or moderately-emetogenic chemotherapy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4855/Sancuso/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4855/Sancuso/</guid>
</item>

<item>
<pubDate>Wed, 12 Nov 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Akten</title>
<description><![CDATA[ The FDA recently approved Akten (lidocaine ophthalmic) a topical anesthetic for use during brief ophthalmic procedures. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4853/Akten/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4853/Akten/</guid>
</item>

<item>
<pubDate>Wed, 05 Nov 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Cleviprex</title>
<description><![CDATA[ The FDA recently approved Cleviprex (clevidipine), an intravenous dihydropyridine calcium channel blocker used for the short-term treatment of hypertension when oral therapy is not feasible. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4840/Cleviprex/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4840/Cleviprex/</guid>
</item>

<item>
<pubDate>Wed, 22 Oct 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Nplate</title>
<description><![CDATA[ Nplate (romiplostim), a thrombopoietin receptor agonist, was recently launched for the treatment of chronic immune (idiopathic) thrombocytopenia purpura (ITP) in adult patients with an insufficient response to standard therapies and an increased risk of bleeding. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4835/Nplate/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4835/Nplate/</guid>
</item>

<item>
<pubDate>Wed, 08 Oct 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Primalev</title>
<description><![CDATA[ Primalev (acetaminophen/oxycodone) was recently launched for the treatment of moderate to moderate-severe pain, and features a lower strength of acetaminophen compared to similar products. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4832/Primalev/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4832/Primalev/</guid>
</item>

<item>
<pubDate>Wed, 24 Sep 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Rotarix</title>
<description><![CDATA[ The FDA has approved Rotarix (rotavirus vaccine, live oral), a vaccine for the prevention of rotavirus gastroenteritis in infants and children. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4829/Rotarix/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4829/Rotarix/</guid>
</item>

<item>
<pubDate>Wed, 17 Sep 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Fusilev</title>
<description><![CDATA[ The FDA has approved Fusilev (levoleucovorin), a folate analog indicated for rescue therapy after high-dose methotrexate. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4825/Fusilev/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4825/Fusilev/</guid>
</item>

<item>
<pubDate>Wed, 20 Aug 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Alvesco</title>
<description><![CDATA[ The FDA has approved Alvesco (ciclesonide inhaled), an inhaled corticosteroid for maintenance therapy of asthma in adults and adolescents 12 years and older. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4817/Alvesco/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4817/Alvesco/</guid>
</item>

<item>
<pubDate>Wed, 13 Aug 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Ocella</title>
<description><![CDATA[ The FDA has approved Ocella (drospirenone/ethinyl estradiol), a branded generic for Yasmin, for oral contraception. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4813/Ocella/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4813/Ocella/</guid>
</item>

<item>
<pubDate>Wed, 06 Aug 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Pentacel</title>
<description><![CDATA[ The FDA has approved Pentacel (diphtheria/tetanus toxoids and acellular pertussis/poliovirus, inactivated/Haemophilus b vaccine) for immunization against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b for children 6 weeks through 4 years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4811/Pentacel/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4811/Pentacel/</guid>
</item>

<item>
<pubDate>Wed, 30 Jul 2008 08:00:00 GMT</pubDate>
<title>New Monograph for Kinrix</title>
<description><![CDATA[ The FDA has approved Kinrix (diphtheria/tetanus toxoids and acellular pertussis/poliovirus, inactivated vaccine) for combination immunization in children 4-6 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1024806/Kinrix/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1024806/Kinrix/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 23 Jul 2008 08:00:00 GMT</pubDate>
<title>New Monograph for zaleplon</title>
<description><![CDATA[ First-time generic formulations for zaleplon are now available.  Zaleplon is equivalent to Sonata, which is indicated for the short-term treatment of insomnia (sleep-onset type). Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2052/zaleplon/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2052/zaleplon/</guid>
</item>

<item>
<pubDate>Wed, 16 Jul 2008 08:00:00 GMT</pubDate>
<title>New Monograph for Risperidone</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for risperidone.  Risperidone is equivalent to Risperdal, which is indicated for the treatment of schizophrenia and the acute mania of bipolar disorder in adults and children. It is also approved for irritability symptoms in children with autistic disorder. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1199/risperidone/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1199/risperidone/</guid>
</item>

<item>
<pubDate>Wed, 09 Jul 2008 08:00:00 GMT</pubDate>
<title>New Monthly Dosing for Actonel</title>
<description><![CDATA[ The FDA has approved once-monthly dosing of Actonel (risedronate) for the prevention and treatment of postmenopausal osteoporosis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/101356/Actonel/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/101356/Actonel/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 02 Jul 2008 08:00:00 GMT</pubDate>
<title>New Black Box Warning for Conventional Antipsychotics</title>
<description><![CDATA[ The FDA has reviewed data indicating that conventional antipsychotics are also associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. In 2005, the same black box warning was added to the atypical antipsychotics.  Neither conventional nor atypical antipsychotics are approved for dementia-related psychosis.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b220/haloperidol/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b220/haloperidol/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 25 Jun 2008 08:00:00 GMT</pubDate>
<title>Expanded Indication for Advair Diskus</title>
<description><![CDATA[ The FDA has approved Advair Diskus (fluticasone/salmeterol inhaled) for maintenance therapy of COPD, which now includes the treatment of emphysema as well as chronic bronchitis.  Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1012444/Advair+Diskus/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1012444/Advair+Diskus/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 18 Jun 2008 08:00:00 GMT</pubDate>
<title>New Black Box Warning for Regranex</title>
<description><![CDATA[ The prescribing information for Regranex (becaplermin topical) now includes a black box warning.  An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of Regranex in a post-marketing retrospective cohort study.  Regranex should only be used when the benefits can be expected to outweigh the risks. Use with caution in patients with known malignancy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10b1169/Regranex/Black+Box+Warnings/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10b1169/Regranex/Black+Box+Warnings/</guid>
</item>

<item>
<pubDate>Wed, 11 Jun 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Relistor</title>
<description><![CDATA[ The FDA has approved Relistor (methylnaltrexone) to treat opioid-induced constipation. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4788/Relistor/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4788/Relistor/</guid>
</item>

<item>
<pubDate>Wed, 04 Jun 2008 08:00:00 GMT</pubDate>
<title>Additional Indication for Amitiza</title>
<description><![CDATA[ The FDA has approved Amitiza (lubiprostone) to treat irritable bowel syndrome with constipation in women, making it the first drug to win approval for this condition. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1014306/Amitiza/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1014306/Amitiza/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 28 May 2008 08:00:00 GMT</pubDate>
<title>New Dosage Form for Paroxetine</title>
<description><![CDATA[ The FDA has approved a first-time generic extended-release form of paroxetine.  Paroxetine ER is equivalent to Paxil CR, which is indicated for the treatment of major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysmorphic disorder. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1011094/paroxetine/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1011094/paroxetine/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 21 May 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Ropinirole</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for ropinirole.  Ropinirole is equivalent to Requip, which is indicated for the treatment of moderate to severe primary restless legs syndrome and for Parkinsons disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1175/ropinirole/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1175/ropinirole/</guid>
</item>

<item>
<pubDate>Wed, 14 May 2008 08:00:00 GMT</pubDate>
<title>Adult Indication and Additional Capsule Sizes for Vyvanse</title>
<description><![CDATA[ The FDA has approved Vyvanse (lisdexamfetamine) for the treatment of ADHD in adults.  It is also now available in 20 mg, 40 mg, and 60 mg capsule strengths. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4679/Vyvanse/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4679/Vyvanse/</guid>
</item>

<item>
<pubDate>Wed, 07 May 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Pristiq</title>
<description><![CDATA[ The FDA has approved Pristiq (desvenlafaxine), the major active metabolite of venlafaxine, for the treatment of major depressive disorder in adults. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4775/Pristiq/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4775/Pristiq/</guid>
</item>

<item>
<pubDate>Wed, 30 Apr 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Fenoglide</title>
<description><![CDATA[ The FDA has approved Fenoglide (fenofibrate) for the treatment of hyperlipidemia, mixed dyslipidemia, or hypertriglyceridemia. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4773/Fenoglide/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4773/Fenoglide/</guid>
</item>

<item>
<pubDate>Wed, 23 Apr 2008 08:00:00 GMT</pubDate>
<title>Pediatric Indication for Reyataz</title>
<description><![CDATA[ The FDA has approved Reyataz (atazanavir) for the treatment of HIV infection in patients 6-17 years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1023479/Reyataz/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1023479/Reyataz/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 16 Apr 2008 08:00:00 GMT</pubDate>
<title>Additional Indication for Aloxi</title>
<description><![CDATA[ The FDA has approved Aloxi (palonosetron) for the prevention of postoperative nausea and vomiting for up to 24 hours following surgery. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1013481/Aloxi/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1013481/Aloxi/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 09 Apr 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Renvela</title>
<description><![CDATA[ The FDA has approved Renvela (sevelamer) for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4760/Renvela/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4760/Renvela/</guid>
</item>

<item>
<pubDate>Wed, 02 Apr 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Treanda</title>
<description><![CDATA[ The FDA has approved Treanda (bendamustine) for the treatment of chronic lymphocytic leukemia (CLL) in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4759/Treanda/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4759/Treanda/</guid>
</item>

<item>
<pubDate>Wed, 26 Mar 2008 08:00:00 GMT</pubDate>
<title>New Dosage Forms for OxyContin</title>
<description><![CDATA[ OxyContin is now available in an expanded array of tablet strengths.  The new extended-release tablets are 15 mg, 30 mg, and 60 mg.  The 60 mg tablets are only to be used in opioid-tolerant patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1011084/OxyContin/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1011084/OxyContin/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 19 Mar 2008 08:00:00 GMT</pubDate>
<title>Additional Pediatric Indication for Abilify</title>
<description><![CDATA[ The FDA has approved Abilify for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features in patients 10-17 years of age. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1023259/Abilify/Pediatric+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1023259/Abilify/Pediatric+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 12 Mar 2008 08:00:00 GMT</pubDate>
<title>Neuropsychiatric Events with Tamiflu</title>
<description><![CDATA[ The occurrence of neuropsychiatric events associated with the use of Tamiflu, in patients with influenza, has been noted by the FDA. These symptoms, as described in post marketing data, include delirium and abnormal behavior leading to injury, and in some cases resulting in fatalities. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. Patients with influenza should be closely monitored for signs of abnormal behavior. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1052172/Tamiflu/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1052172/Tamiflu/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 05 Mar 2008 08:00:00 GMT</pubDate>
<title>Hepatotoxicity Warning for Tysabri</title>
<description><![CDATA[ The FDA has reported liver injury during use of Tysabri. Signs included markedly elevated hepatic enzymes and total bilirubin, which occurred as early as six days after the first dose. These elevated lab values, without evidence of obstruction, are recognized as an important predictor of severe injury that may lead to death or the need for a transplant in some patients. Tysabri should be discontinued in patients with jaundice or other evidence of significant liver injury. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1054015/Tysabri/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1054015/Tysabri/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 27 Feb 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Pantoprazole</title>
<description><![CDATA[ The FDA has approved first-time generic tablet formulations for pantoprazole. Pantoprazole is equivalent to Protonix, and is indicated for erosive esophagitis and hypersecretory conditions. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2224/pantoprazole/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2224/pantoprazole/</guid>
</item>

<item>
<pubDate>Wed, 20 Feb 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Balsalazide</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for balsalazide. Balsalazide is equivalent to Colazal, which is indicated for mild-moderate active ulcerative colitis in both adults and children. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2346/balsalazide/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2346/balsalazide/</guid>
</item>

<item>
<pubDate>Wed, 13 Feb 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Alendronate</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for alendronate. Alendronate is equivalent to Fosamax, which is indicated for the prevention and treatment of osteoporosis and the treatment of osteotic Pagets disease. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a769/alendronate/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a769/alendronate/</guid>
</item>

<item>
<pubDate>Wed, 06 Feb 2008 08:00:00 GMT</pubDate>
<title>Suicidality and Antiepileptic Drugs</title>
<description><![CDATA[ The FDA has analyzed reports of suicidality from placebo-controlled clinical studies of drugs used to treat epilepsy as well as other conditions. Patients receiving AEDs had approximately twice the risk of suicidal behavior or ideation. The relative risk was higher in patients with epilepsy compared to patients who were treated for other conditions. All patients currently taking or starting any AED should be closely monitored for behavior changes that could indicate the emergence or worsening of suicidal thoughts, behavior or depression. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10c1318/Topamax/Safety+Monitoring/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10c1318/Topamax/Safety+Monitoring/</guid>
</item>

<item>
<pubDate>Wed, 30 Jan 2008 08:00:00 GMT</pubDate>
<title>Additional Neuropsychiatric Warnings for Chantix</title>
<description><![CDATA[ The labeling for Chantix has been updated with a warning to observe patients for serious neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation and suicidal behavior. These symptoms, as well as a worsening of pre-existing psychiatric illness, may be complicated by the symptoms of nicotine withdrawal in patients who stopped smoking. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1054391/Chantix/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1054391/Chantix/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 23 Jan 2008 08:00:00 GMT</pubDate>
<title>Amantadine and Rimantadine on Hold for Influenza A Therapy and Prophylaxis</title>
<description><![CDATA[ On the recommendation of the ACIP (Advisory Committee on Immunization Practices), for 2007-08 neither amantadine nor rimantadine should be used for the treatment or prevention of influenza type A in the United States.  Currently circulating influenza A viruses show widespread resistance to these medications. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/101132/amantadine/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/101132/amantadine/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 16 Jan 2008 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Granisetron</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for granisetron.  Granisetron is equivalent to Kytril, which is indicated for post-operative nausea and vomiting as well as nausea and vomiting associated with chemotherapy, and x-ray therapy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a1567/granisetron/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a1567/granisetron/</guid>
</item>

<item>
<pubDate>Wed, 09 Jan 2008 08:00:00 GMT</pubDate>
<title>Bisphosphonates and Severe Musculoskeletal Pain</title>
<description><![CDATA[ The FDA has emphasized the possibility of severe and sometimes incapacitating bone, joint, and/or muscle pain in patients taking bisphosphonates. Although severe musculoskeletal pain is included in the prescribing information for all bisphosphonates, this association may be overlooked by healthcare professionals, delaying diagnosis, prolonging pain and/or impairment, and necessitating the use of analgesics. The severe musculoskeletal pain may occur within days, months, or years after starting a bisphosphonate. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1051479/Aredia/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1051479/Aredia/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 02 Jan 2008 08:00:00 GMT</pubDate>
<title>DEA Restricts Distribution of 40 mg Methadone Tablet</title>
<description><![CDATA[ Due to a reported increase in methadone-related adverse events, manufacturers have agreed to restrict distribution of this formulation to only those facilities authorized for detoxification and maintenance treatment of opioid addiction, and hospitals.  The 40 mg methadone formulation is only indicated for the detoxification and maintenance treatment of opioid addiction.  The 5 mg and 10 mg formulations indicated for the treatment of pain will continue to be available to all authorized registrants, including retail pharmacies. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10153/methadone/Adult+Dosing/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10153/methadone/Adult+Dosing/</guid>
</item>

<item>
<pubDate>Wed, 19 Dec 2007 08:00:00 GMT</pubDate>
<title>Additional Black Box Warning for Carbamazepine</title>
<description><![CDATA[ The FDA has informed healthcare professionals that the risk of dangerous or even fatal skin reactions (e.g., Stevens Johnson syndrome and toxic epidermal necrolysis) are higher in patients with the HLA-B*1502 allele. This allele occurs almost exclusively in Asian patients. Thus, patients with genetically at-risk ancestry should be screened before starting treatment with carbamazepine. Patients testing positive should not start therapy unless benefit outweighs risk. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a166/carbamazepine/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a166/carbamazepine/</guid>
</item>

<item>
<pubDate>Wed, 12 Dec 2007 08:00:00 GMT</pubDate>
<title>Updated Labeling for Desmopressin Adds Warnings and Removes Indication</title>
<description><![CDATA[ The FDA has requested the prescribing information for all desmopressin products (DDAVP, Minirin, Stimate, generics) be updated to include important information about the risk of severe hyponatremia and seizures. Due to these warnings, desmopressin should not be used in patients with hyponatremia or a history or hyponatremia. Additionally, the desmopressin intranasal formulations are no longer indicated for the treatment of primary nocturnal enuresis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10399/desmopressin/Contraindications+Cautions/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10399/desmopressin/Contraindications+Cautions/</guid>
</item>

<item>
<pubDate>Wed, 05 Dec 2007 08:00:00 GMT</pubDate>
<title>Reports of Suicidal Ideation, Aggressive Behavior, and Drowsiness with Chantix</title>
<description><![CDATA[ The FDA is reviewing recent reports of suicidal ideation and aggressive and erratic behavior in patients who have taken Chantix, a smoking cessation product approved in May 2006. In addition, there are reports of patients on Chantix experiencing drowsiness that affected their ability to drive or operate machinery. The FDA recommends monitoring patients on Chantix for mood and behavioral changes and informing patients to use caution when driving or operating machinery. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1054391/Chantix/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1054391/Chantix/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 28 Nov 2007 08:00:00 GMT</pubDate>
<title>Updated Black Box Warnings for Erythropoiesis-Stimulating Agents</title>
<description><![CDATA[ The FDA has recently approved revised labeling for Aranesp, Epogen, and Procrit, erythropoiesis-stimulating agents (ESA) used to treat certain types of anemia. The updated black box warnings discuss tumor growth and shortened survival in cancer patients and an increased risk of serious cardiovascular events and mortality in chronic renal failure patients when Hgb >12 g/dL are achieved with ESA therapy. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2480/Aranesp/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2480/Aranesp/</guid>
</item>

<item>
<pubDate>Wed, 21 Nov 2007 08:00:00 GMT</pubDate>
<title>Additional Black Box Warning for Avandia</title>
<description><![CDATA[ The black box warning for Avandia has been updated to include new information on the potential increased risk of myocardial ischemic events. While available data are inconclusive at this time, healthcare professionals are advised to closely monitor patients for cardiovascular risks. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2049/Avandia/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2049/Avandia/</guid>
</item>

<item>
<pubDate>Wed, 14 Nov 2007 08:00:00 GMT</pubDate>
<title>Zyrtec-D Approved for OTC Use</title>
<description><![CDATA[ The FDA has approved Zyrtec-D (cetirizine/pseudoephedrine) for nonprescription use for the relief of symptoms due to hay fever or other respiratory allergies, for reducing swelling of nasal passages, for the relief of sinus congestion and pressure, and for restoring freer breathing through the nose. Zyrtec-D will be subject to sales restrictions imposed by the federal Combat Methamphetamine Epidemic Act because it contains pseudoephedrine. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2627/Zyrtec-D+12+Hour/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2627/Zyrtec-D+12+Hour/</guid>
</item>

<item>
<pubDate>Wed, 07 Nov 2007 08:00:00 GMT</pubDate>
<title>Trasylol Withdrawn from US Market</title>
<description><![CDATA[ The FDA has announced that the marketing for Trasylol (aprotinin) has been suspended pending a review of preliminary results from the Canadian study suggesting an increased risk of death. Trasylol was used to control bleeding during coronary artery bypass graft surgery. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a2630/Trasylol/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a2630/Trasylol/</guid>
</item>

<item>
<pubDate>Wed, 31 Oct 2007 08:00:00 GMT</pubDate>
<title>New Warnings for Provigil</title>
<description><![CDATA[ The prescribing information for Provigil (modafinil) has recently been revised to include warnings on serious rash, including Stevens-Johnson Syndrome, hypersensitivity reactions, and psychiatric symptoms. Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1052276/Provigil/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1052276/Provigil/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 24 Oct 2007 08:00:00 GMT</pubDate>
<title>Reports of Acute Pancreatitis with Byetta Use</title>
<description><![CDATA[ The FDA has reviewed 30 postmarketing reports of acute pancreatitis in patients taking Byetta (exenatide), and an association between Byetta and acute pancreatitis is suspected. Byetta is indicated for the treatment of type 2 diabetes mellitus in adult patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1054155/Byetta/Adverse+Reaction/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1054155/Byetta/Adverse+Reaction/</guid>
</item>

<item>
<pubDate>Wed, 17 Oct 2007 08:00:00 GMT</pubDate>
<title>IV Compatibility Information</title>
<description><![CDATA[ The IV compatibility information in Epocrates Rx has recently been updated. Additions include 3 new drugs (aripiprazole, caspofungin, and ropivacaine) in the IV compatability checker and new information for cefepime and nesiritide. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/</link>
<guid isPermaLink="false">https://online.epocrates.com/</guid>
</item>

<item>
<pubDate>Wed, 10 Oct 2007 08:00:00 GMT</pubDate>
<title>Epocrates ID Update</title>
<description><![CDATA[ The following sections of Epocrates ID have recently been reviewed and revised: <strong>CNS, ENT, Genital, Lung, Other, Skin/Soft Tissue, Systemic,</strong> and <strong>Urinary Tract</strong>. Furthermore, there are new additions to the <strong>Pediatrics</strong> sections of ID, including neonatal meningitis, omphalitis, and septic shock. In the coming months, the Epocrates Infectious Disease team will be adding significantly more treatments for pediatric patients. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>http://www.epocrates.com/products/rxpro/index.html</link>
<guid isPermaLink="false">http://www.epocrates.com/products/rxpro/index.html</guid>
</item>

<item>
<pubDate>Wed, 10 Oct 2007 08:00:00 GMT</pubDate>
<title>New Vaccine Monograph for Afluria</title>
<description><![CDATA[ The FDA has approved Afluria, a new influenza vaccine, for active immunization against influenza virus subtypes A and type B in individuals >18 years of age for the 2007-2008 flu season. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1014696/Afluria/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1014696/Afluria/</guid>
</item>

<item>
<pubDate>Wed, 03 Oct 2007 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Xyzal</title>
<description><![CDATA[ The FDA has approved Xyzal (levocetirizine) for the symptomatic relief of seasonal and perennial allergic rhinitis and for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children at least 6 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4691/Xyzal/</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4691/Xyzal/</guid>
</item>

<item>
<pubDate>Wed, 26 Sep 2007 08:00:00 GMT</pubDate>
<title>New Lower Strength of Soma Approved</title>
<description><![CDATA[ The FDA has approved a 250 mg strength of Soma (carisoprodol) for the relief of discomfort associated with acute, painful musculoskeletal conditions. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1011247/Soma/Adult+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1011247/Soma/Adult+Dosing</guid>
</item>

<item>
<pubDate>Wed, 19 Sep 2007 08:00:00 GMT</pubDate>
<title>Additional Indications for Short Course Levaquin Therapy</title>
<description><![CDATA[ The FDA has approved Levaquin 750 mg as a 5-day, once daily regimen for the treatment of complicated urinary tract infection and acute pyelonephritis. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/101862/Levaquin/Adult+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/101862/Levaquin/Adult+Dosing</guid>
</item>

<item>
<pubDate>Wed, 12 Sep 2007 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Carvedilol</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for carvedilol. Carvedilol is equivalent to Coreg, which is indicated for the treatment of hypertension, chronic heart failure, and left ventricular dysfunction following myocardial infarction. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a534/carvedilol</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a534/carvedilol</guid>
</item>

<item>
<pubDate>Wed, 05 Sep 2007 08:00:00 GMT</pubDate>
<title>New Drug Monograph for Bendroflumethiazide/Nadolol</title>
<description><![CDATA[ The FDA has approved first-time generic formulations for bendroflumethiazide/nadolol for the treatment of hypertension in adult patients. Bendroflumethiazide/nadolol is equivalent to Corzide. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a543/bendroflumethiazide-nadolol</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a543/bendroflumethiazide-nadolol</guid>
</item>

<item>
<pubDate>Wed, 29 Aug 2007 08:00:00 GMT</pubDate>
<title>Additional indications for Risperdal in Children and Adolescents</title>
<description><![CDATA[ The FDA has approved the use of Risperdal (risperidone) for the treatment of schizophrenia in adolescents aged 13-17 years old and for the treatment of acute manic or mixed episodes associated with bipolar disorder in children and adolescents aged 10-17 years old. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1021200/Risperdal/Pediatric+Dosing</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1021200/Risperdal/Pediatric+Dosing</guid>
</item>

<item>
<pubDate>Wed, 22 Aug 2007 08:00:00 GMT</pubDate>
<title>New Black Box Warnings for Thiazolidinediones</title>
<description><![CDATA[ The FDA has determined that the thiazolidinedione class of anti-diabetics needed updated labeling with a boxed warning emphasizing the risk of heart failure. Patients should be observed carefully for signs and symptoms of heart failure after initiation of therapy. Use of these drugs should be reconsidered if heart failure develops, and use is not recommended in patients with symptomatic heart failure. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
</item>

<item>
<pubDate>Wed, 15 Aug 2007 08:00:00 GMT</pubDate>
<title>Revised ACIP Recommendations for Meningococcal Vaccination</title>
<description><![CDATA[ The Advisory Committee on Immunization Practices (ACIP) recently revised their recommendations to include routine vaccination of all individuals 11-18 years of age with one dose of the meningococcal conjugate (MCV4) vaccine. Children 11-12 years of age should be routinely vaccinated at their 11-12 year healthcare visit. Previously unvaccinated individuals 11-18 years of age should be vaccinated at the earliest opportunity. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
</item>

<item>
<pubDate>Wed, 08 Aug 2007 08:00:00 GMT</pubDate>
<title>Omacor (omega-3-acid ethyl esters)</title>
<description><![CDATA[ Used for the treatment of hypertriglyceridemia, has been confused with Amicar (aminocaproic acid), a drug used to treat excessive bleeding from fibrinolysis, in part because both are available in 1 g oral dosage forms. To minimize potential errors in the future, the brand name Omacor has been changed to Lovaza, which is now available. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/10a4013/Lovaza</link>
<guid isPermaLink="false">https://online.epocrates.com/u/10a4013/Lovaza</guid>
</item>

<item>
<pubDate>Wed, 01 Aug 2007 08:00:00 GMT</pubDate>
<title>ceftriaxone (Rocephin, generic)</title>
<description><![CDATA[ Updated monographs based on recent MedWatch Safety Alert regarding revisions to ceftriaxone prescribing information; revisions include new information on the risk associated with concomitant use of ceftriaxone and parenteral calcium or calcium-containing products. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1031624/ceftriaxone</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1031624/ceftriaxone</guid>
</item>

<item>
<pubDate>Wed, 25 Jul 2007 08:00:00 GMT</pubDate>
<title>ProQuad (measles/mumps/rubella/varicella vaccine, live)</title>
<description><![CDATA[ Updated monograph to reflect current availability status; vaccine will be unavailable through the remainder of 2007. Learn more at <a href="http://www.epocrates.com/">www.epocrates.com</a> ]]></description>
<link>https://online.epocrates.com/u/1064242/ProQuad</link>
<guid isPermaLink="false">https://online.epocrates.com/u/1064242/ProQuad</guid>
</item>

</channel>
</rss>